Format

Send to

Choose Destination
J Infect. 2016 Jul 5;72 Suppl:S77-82. doi: 10.1016/j.jinf.2016.04.026. Epub 2016 May 21.

Recognising early onset neonatal sepsis: an essential step in appropriate antimicrobial use.

Author information

1
Division of Pediatric Infectious Diseases, Immunology and Rheumatology, Department of Pediatrics, Erasmus MC University Medical Center, Rotterdam, the Netherlands. Electronic address: w.vanherk@erasmusmc.nl.
2
Department of Pediatrics, Division of Neonatal and Pediatric Intensive Care Unit, Children's Hospital, 6000 Luzern 16, Switzerland. Electronic address: martin.stocker@luks.ch.
3
Division of Pediatric Infectious Diseases, Immunology and Rheumatology, Department of Pediatrics, Erasmus MC University Medical Center, Rotterdam, the Netherlands. Electronic address: a.vanrossum@erasmusmc.nl.

Abstract

Early diagnosis and timely treatment of early onset neonatal sepsis (EOS) are essential to prevent life threatening complications. Subtle, nonspecific clinical presentation and low predictive values of biomarkers complicate early diagnosis. This uncertainty commonly results in unnecessary and prolonged empiric antibiotic treatment. Annually, approximately 395,000 neonates (7.9% of live term births) are treated for suspected EOS in the European Union, while the incidence of proven EOS varies between 0.01 and 0.53 per 1000 live births. Adherence to guidelines for the management of suspicion of EOS is poor. Pragmatic approaches to minimise overtreatment in neonates with suspected EOS, using combined stratified risk algorithms, based on maternal and perinatal risk factors, clinical characteristics of the neonate and sequential biomarkers are promising.

KEYWORDS:

Early onset neonatal sepsis; Guidelines; Neonatal infection; Neonates; Perinatal infections; Procalcitonin; Sepsis

PMID:
27222092
DOI:
10.1016/j.jinf.2016.04.026
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center